Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Investing Activities: 2015-2024

Historic Cash from Investing Activities for Sunshine Biopharma (SBFM) over the last 9 years, with Dec 2024 value amounting to -$2.3 million.

  • Sunshine Biopharma's Cash from Investing Activities rose 82.36% to -$118,295 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year increase of 43.03%. This contributed to the annual value of -$2.3 million for FY2024, which is 253.71% down from last year.
  • According to the latest figures from FY2024, Sunshine Biopharma's Cash from Investing Activities is -$2.3 million, which was down 253.71% from -$656,150 recorded in FY2023.
  • Sunshine Biopharma's Cash from Investing Activities' 5-year high stood at -$1,191 during FY2020, with a 5-year trough of -$14.6 million in FY2022.
  • In the last 3 years, Sunshine Biopharma's Cash from Investing Activities had a median value of -$2.3 million in 2024 and averaged -$5.9 million.
  • As far as peak fluctuations go, Sunshine Biopharma's Cash from Investing Activities surged by 95.51% in 2023, and later plummeted by 253.71% in 2024.
  • Yearly analysis of 4 years shows Sunshine Biopharma's Cash from Investing Activities stood at -$1,191 in 2020, then reached -$14.6 million in 2022, then skyrocketed by 95.51% to -$656,150 in 2023, then plummeted by 253.71% to -$2.3 million in 2024.